Innovate Biopharmaceuticals, Inc. (INNT) Trading at $24.87 after Raise

June 29, 2018 - By Robert Judd

Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) increased significantly to $24.87. Barchart.com reported it on Jun, 29. It has $638.92M MC. The company’s valuation will be $31.95 million more at $26.11 PT.

For more Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) news announced briefly go to: Benzinga.com, Nasdaq.com, Benzinga.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “40 Stocks Moving In Wednesday’s Mid-Day Session” announced on June 27, 2018, “The 3 Best Biotech Stocks of 2018 So Far” on June 28, 2018, “44 Biggest Movers From Yesterday” with a publish date: June 26, 2018, “Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of …” and the last “Innovate Biopharmaceuticals, Inc. added to membership of Russell 3000®, 2000® and the Russell Microcap® Indexes” with publication date: June 25, 2018.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics.The firm is valued at $638.92 million. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH).Currently it has negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: